PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provides Chinese medicine services and CCMG products. In addition, the company engages in the plantation and trading of raw Chinese herbs; manufacture and sale of traditional Chinese medicine decoction pieces; provision of modernized Chinese medicine services, Chinese medical diagnostic services; and research and development of new products and bio-based polymeric materials. Further, It operates an online platform. PuraPharm Corporation Limited was incorporated in 1998 and is headquartered in Tai Po, Hong Kong.
Frequently asked questions
What sector does Purapharm Corp Ltd (1498) operate in?
Purapharm Corp Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Purapharm Corp Ltd (1498) current stock price?
As of the latest data, Purapharm Corp Ltd stock price is HK$0.26, with a previous close of HK$0.26.
What is Purapharm Corp Ltd (1498) current market capitalization?
Purapharm Corp Ltd market cap is approximately 136.44 million.
What is Purapharm Corp Ltd (1498) EBITDA?
Purapharm Corp Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 14.08 million.
Does Purapharm Corp Ltd (1498) pay dividends?
No. Purapharm Corp Ltd does not pay a dividend.
What is Purapharm Corp Ltd (1498) beta (volatility) score?
Purapharm Corp Ltd has a beta of 0.203, indicating lower volatility than the overall market.
